Germany Decides On Added Benefit Of Gilead’s Veklury For COVID-19
The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.
You may also be interested in...
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.
The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.